Please type a plus sign (+) inside this box
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

Sheet of 1

Complete if Known					
Application Number	10/734,787				
Filing Date	12-12-2003				
First Named Inventor	THIERRY CANTON, ET AL				
Group Art Unit					
Examiner Name					
Attorney Docket Number	FRAV2002/0036 - US - NP				

	U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.1	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
CK		6,221,897		FRICK, ET AL	04-24-2001					
CX		6,245,744		FRICK, ET AL	06-12-2001					
					 					
										
					<u> </u>					
					<u> </u>					
						•				
				·		·				

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office	Foreign Patent Doc 3 Number ⁴	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
GL		wo	01/56579		BISGAIER, ET AL	08-09-2001		
		wo	01/96311		ROBI, ET AL	12-20-2001		
		wo	97/49736		FORSTER, ET AL	12-31-1997		
		wo	99/38498		BISGAIER, ET AL	08-05-1999		
		wo	99/48488		YANKNER	09-30-1999		
CX		wo	99/64409		FRICK, ET AL	12-16-1999		
		├				 		1
								H
								П

Examiner	() - · · i	Date		Ι.	1
Signatura	(m. Kan - 1		4	126	10/0
Signature	0 100	 Considered	· /	~~	700

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	ィ
---	---

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitu	te for form 1449B	/PTO		Complete if Known			
		_		Application Number	10/734,787 12-12-2003		
INFO	DRMATIC	ON D	ISCLOSURE	Filing Date			
STA	TEMENT	T RY	APPLICANT	First Named Inventor	THIERRY CANTON, ET AL		
017			All I EloAll I	Group Art Unit			
	(use as mai	ny sheet	s as necessary)	Examiner Name			
heet 2 of 2				Attorney Docket Number	FRAV2002/0036 - US - NP		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
GC		FASSBENDER K., ET AL, Simvastatin Strongly Reduces Levels of Alzheimer's Disease Beta-Amylold Peptides Abeta 42 and Abeta 40 in Vitro And In Vivo, Proceedings of the National Academy of Science of the United States of America (2001, Volume 98, Issue 10, pp. 5856-5861)						
		HARTMAN T., Cholesterol, Abeta and Alzheimer's Disease, Trends in Neuroscience (2001, Volume 24, Issue 11, pp. s45-s48)						
		REFOLO L. M., ET AL, A Cholesterol-Lowering Drug Reduces Beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease, Neurobiology of Disease (2001, Volume 8, Issue 5, pp. 890-899)						
GK		RODRIGUES C. M. P. ET AL, Amyloid B-Peptide Disrupts Mitochondrial Membrane Lipid And Proteinsstructure, Biochemical and Biophysical Research Communications (2001, Volume 281, Issue 2, pp. 468-474						

	Examiner Signature	G. Kozin	Date Considered	9/26/	06
•	0.3		Considered	1	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.